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West Nile Virus: USA and Canada 
West Nile virus (WNV) has spread unchecked across the USA and Canada during 2002. In the USA as of 6 November 2002, the human case 
totals for 2002 that have been reported to CDC/Arbonet or compiled in direct communication with state and local health officials include 3507 
laboratory-positive human cases of WNV with 206 deaths that have been reported in 38 states and the District of Columbia 
(http:/lwww.cdc.gov/od/oc/media/wncount.htm). During 2002, evidence of WNV infections in birds, humans, mosquitoes, and other animals, 
primarily horses, has been documented in 43 states and the District of Columbia (http://www.who.int/disease-outbreak-news/n2~2/october/ 
30october2002,html). The only states in which WNV has not been demonstrated are Alaska, Hawaii, Oregon, Idaho, Nevada, Utah, and Arizona. 
The states that have been most affected are Illinois, which, with 719 human cases and 46 deaths, accounts for approximately one-fifth of the 
human cases in the USA during 2002, Michigan, with 483 human cases and 40 deaths, Ohio, with 413 human cases and 21 deaths, and Louisiana, 
in which there have been 321 human cases and 19 deaths. 
During the summer, at a time when there had been 58 cases and four deaths in the state, Louisiana’s Governor, Mike Foster, declared a 
state of emergency as a result of WNV. With respect to public health and preventable death, it should be noted that Louisiana ranked second in 
the USA by rate of child victims murdered with a handgun from 1995 to 1999, years during which there were 146 children aged 1-17 years who 
were the victims of handgun homicide in Lousiana. The public’s perception of public health threats in the USA means that, sadly, it is not politically 
feasible for a Governor to declare a state of emergency and seek federal assistance as a result of firearm-related homicide, but it is both politically 
acceptable and merits media coverage to do so for a novel mosquito-borne disease that has substantially less public health impact. 
In Canada. as of 5 November 2002, Health Canada has reported (http://www.who.int/disease-outbreaknews/n2002/november/6november 
2002,html) a total number of 121 human cases of WNV infection. This includes 65 suspected cases (with five deaths) and 56 confirmed cases, 
which includes one death and one death that is under investigation, One confirmed case is resident in the province of Alberta (probably acquired 
in the USA), one suspected case and seven confirmed cases are resident in the province of Quebec, and the remaining 64 suspected cases and 48 
confirmed cases are resident in the province of Ontario (one of which is thought to have been acquired in the USA). 
In other provinces (http://www.hc-sc.gc.ca/pphb-dgspsp/wnv-vwn/index,html), monitoring efforts have also identified WNV in birds in Nova 
Scotia. birds, horses, and mosquitoes in Manitoba, and in birds and horses in Saskatchewan. 
Vancomycin-resistant Staphylococcus aureus (VRSA) 
The first two clinical isolates of Staphylococcus aureus found to contain the vanA gene have appeared in the USA in recent months. Although 
conjugative transfer of vanA from enterococci to S. aureus has been previously demonstrated in vitro,none of the acquired vancomycin resistance 
determinants found in enterococci (vanA, vanB, vanD, vanE, vanF, and vanG) have ever been identified in clinical isolates of S. aureus before. 
The first VRSA strain, cultured from a patient in Michigan in June, was fully resistant to vancomycin (MIC > 128 ug/mL) and teicoplanin 
(MIC 32 ug/mL). as determined by a broth microdilution method (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5126al.htm). It was isolated 
from a 40-year-old diabetic with peripheral vascular disease and chronic renal failure who was receiving outpatient dialysis. Multiple courses of 
antimicrobial therapy, including vancomycin, had been prescribed in preceding months for various infections.The VRSA strain was isolated from 
an exit-site swab, a catheter tip, and a chronic foot ulcer swab. Vancomycin-resistant Enterococcus fuecalis (VRE) was also isolated from the foot 
ulcer, suggesting that the vanA resistance determinant may have been acquired through exchange of genetic material between these two 
organisms. The patient received systemic trimethroprim-sulfamethoxazole and aggressive wound management. The isolate was also sensitive in 
vitro to chloramphenicol. linezolid, minocycline, and quinupristin-dalfopristin. No transmission of VRSA to other patients or health care workers 
was found, and increased vigilance and special precautions based on CDC recommendations (http:/lwww.cdc.gov/ncidod/hipllO~2O.pdf.) were 
implemented. 
The second VRSA strain, which came from a patient in Pennsylvania in September, appears to be unrelated to the first VRSA strain from 
Michigan. It was also cultured from a chronic foot ulcer, and had a vancomycin MIC of 32 yg/mL.The isolate contained both the mecA and vanA 
genes, and was susceptible to chloramphenicol, linezolid, minocycline, quinupristin-dalfopristin, rifampin, and trimethoprim-sulfamethoxazole. 
Follow-up investigations on those who came into contact with this patient are ongoing, 
AS noted on ProMED-mail, the first case of VRSA infection and many cases of VISA (vancomycin-intermediate .S. aureus) infection that 
have appeared over the last 5 years or so have occurred in chronic renal failure patients treated with vancomycin for MRSA. The emergence of 
VRSA, which has long been anticipated, emphasizes the need for programs to control the use of antimicrobial drugs, particularly for patients 
with chronic diseases such as those on dialysis units, along with measures to prevent the spread of these highly resistant organisms. 
Hepatitis E in the Central African Republic 
In early October, ProMED-mail reported an epidemic of hepatitis E in the northern suburbs of Bangui, the capital of the Central African Republic 
(CAR). An increase in the number of cases of hepatitis was seen in the preceding 3 months, and an emergency committee comprising officials 
from the Ministry of Health, Medecins saris Frontier, the World Health Organization (WHO), the Institut Pasteur and the National Laboratory 
was set up to tackle the problem. Initial blood tests carried out by the Institut Pasteur revealed that 48 of 98 cases tested positive for hepatitis E 
virus (HEV). Efforts in the CAR are being focused on increasing public awareness of how the virus is spread, providing safe drinking water for 
all, and encouraging proper disposal of sanitary waste. It is hoped that these measures, together with the forthcoming dry season, will help to 
control this epidemic. 
HEV, previously considered to be a calicivirus-like agent but now ranked as a separate unassigned genus, can cause acute sporadic and 
epidemic viral hepatitis. The virus is spread via the fecal-oral route, and the incubation period is 2-7 weeks. Epidemics of the disease most 
commonly arise as a result of the consumption of contaminated drinking water, particularly in the Indian subcontinent. Sporadic cases in endemic 
areas (which include tropical and subtropical regions of Asia, Africa, and Central America) are more likely to be due to ingestion of raw or 
uncooked shellfish or other foodstuffs. 
Increases in HEV prevalence have recently been noted in some developed countries, but the reasons for this are not entirely clear. It seems 
that many of these patients have not traveled to endemic areas. Serologic evidence suggests that the virus may in fact be more widespread than 
originally believed, albeit in less virulent forms. There is also an accumulating body of evidence supporting zoonotic transmission: swine HEV 
and avian HEV are genetically and antigenically related to human HEV, and swine HEV infects chimpanzees, while human HEV infects pigs 
(ProMED-mail archive number 20020724.4856). Other recent ProMED reports include newly identified genotypes from Japan, and a patient co- 
infected with two distinct genotypes (ProMED-mail archive number 20020721.4824). It seems that we may be slowly beginning to understand 
the complex epidemiology of this virus. 
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